【摘要】 目的观察舒必利、奥美拉唑、铝碳酸镁使用三药联合治疗反流性胃炎的疗效及对患者血清人血管活性肠肽(VIP)、白细胞介素-6(IL-6)水平的影响。方法选取2017年8月至2019年7月在河南科技大学第一附属医院治疗的104例反流性胃炎患者,根据随机数字表法将其分为对照组与观察组,每组52例。对照组使用奥美拉唑联合铝碳酸镁治疗,观察组在此基础上使用舒必利治疗。比较两组患者的治疗总有效率和血清VIP、IL-6水平。结果观察组总有效率(96. 15%,50/52)明显高于对照组(84. 62%,44/52),差异有统计学意义(P <0. 05);治疗后,观察组患者的VIP、IL-6水平明显低于对照组(P <0. 05)。结论对反流性胃炎患者采取舒必利、奥美拉唑、铝碳酸镁三药治疗可提高治疗效果,改善患者血清VIP、IL-6水平,应用效果良好。更多还原

【Abstract】 Objective To observe the efficacy of sulpiride,omeprazole,aluminum magnesium carbonate on reflux gastritis and its effect on VIP and IL-6 levels in serum. Methods From August 2017 to July 2019,104 patients with reflux gastritis treated in the Frist Affilicital of Henan University of Science and Technology were selected. And they were divided into control group and observation group according to random allocation,with 52 cases in each group. The patients in the control group were treated with omeprazole combined with aluminum magnesium carbonate. The patients in the observation group was given sulpiride in addition. The total effective rate and the VIP and IL-6 levels in serum were observed in the two groups. Results The total effective rate in the observation group( 96. 15%,50/52)was significantly higher than that in the control group( 84. 62%,44/52,P < 0. 05). After treatment,the levels of VIP and IL-6 in the observation group were significantly lower than those in the control group( P <0. 05). Conclusions Sulpiride,omeprazole,aluminum magnesium carbonate treatment for patients with reflux gastritis can improve the treatment effect,improve the serum VIP and IL-6 levels in patients,and the application effect is good.更多还原